Redwood Grove Capital LLC purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 59,070 shares of the insurance provider's stock, valued at approximately $23,464,000. Humana makes up 5.9% of Redwood Grove Capital LLC's holdings, making the stock its 4th largest holding.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Montag A & Associates Inc. raised its stake in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Johnson Financial Group Inc. acquired a new stake in Humana in the second quarter valued at approximately $26,000. Fideuram Asset Management Ireland dac acquired a new stake in Humana in the fourth quarter valued at approximately $27,000. Trust Co. of Vermont purchased a new position in Humana in the second quarter worth $28,000. Finally, Reflection Asset Management purchased a new position in Humana in the fourth quarter worth $29,000. Hedge funds and other institutional investors own 92.38% of the company's stock.
Humana Trading Up 0.6%
NYSE:HUM opened at $388.92 on Wednesday. The company has a market capitalization of $46.70 billion, a P/E ratio of 36.79, a PEG ratio of 2.20 and a beta of 0.72. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $428.88. The firm has a fifty day simple moving average of $383.88 and a 200-day simple moving average of $285.00.
Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The company had revenue of $40.89 billion during the quarter, compared to analyst estimates of $40.58 billion. During the same quarter last year, the business posted $6.27 EPS. The firm's quarterly revenue was up 26.2% on a year-over-year basis. On average, equities research analysts anticipate that Humana Inc. will post 9.12 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on HUM. Deutsche Bank Aktiengesellschaft assumed coverage on Humana in a report on Thursday, July 30th. They set a "hold" rating for the company. Barclays boosted their target price on Humana from $344.00 to $407.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Morgan Stanley raised Humana from an "underweight" rating to an "equal weight" rating and upped their target price for the company from $249.00 to $370.00 in a research report on Tuesday, August 4th. Jefferies Financial Group upgraded Humana from a "buy" rating to a "buy" rating in a research note on Wednesday, May 20th. Finally, Oppenheimer reissued an "outperform" rating and issued a $405.00 price target on shares of Humana in a report on Thursday, July 30th. Fourteen research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $403.91.
View Our Latest Report on HUM
About Humana
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
See Also
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
